Less Radiation to Healthy Tissues, Fewer Complications for Prostate Cancer Patients
Applicable for tumors anywhere in the body, proton therapy has been used to treat prostate cancer for many years [1,2] with proven success.
Unlike traditional radiation treatments, proton therapy deposits positively charged particles of energy directly into the tumor, leaving no exit dose and lowering the risk of unnecessary exposure to healthy tissue. As such, it also allows for definitive doses of radiation while minimizing adjacent organ exposure in an effort to reduce side effects, making it particularly effective for the following indications:
Localized prostate cancer
- Reduced radiation exposure to surrounding healthy tissues , particularly the rectum and bladder , as compared to IMRT
- Excellent clinical outcomes for early stage prostate cancer following high-dose proton therapy [5-7]
- Significant reduction in gastrointestinal and genitourinary side effects [2,5,6,8-10]
- Excellent clinical outcomes and minimal toxicity following advanced proton therapy with different fractionation schedules [11,12]
- Improved patient-reported quality of life [9,13]
Locally advanced prostate cancer
As compared to photon-based therapy, proton therapy offers:
- Reduced radiation dose to normal structures (including bladder, small bowel, and rectum) during pelvic radiation 
- Minimal gastrointestinal toxicity following treatment for prostate and pelvic lymph nodes 
Salvage treatment for local relapse of prostate cancer
- Early data of a small number of patients demonstrates a high rate of cancer control and acceptable toxicities from proton therapy for prostate cancer and local relapse following cryosurgery or HIFU 
1. Shipley, W.U., et al., Proton radiation as boost therapy for localized prostatic carcinoma. JAMA, 1979. 241(18): p. 1912-5.
2. Slater, J.D., et al., Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys, 2004. 59(2): p. 348-52.
3. Trofimov, A., et al., Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys, 2007. 69(2): p. 444-53.
4. Vargas, C., et al., Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys, 2008. 70(3): p. 744-51.
5. Zietman, A.L., et al., Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol, 2010. 28(7): p. 1106-11.
6. Bryant, C., et al., Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys, 2016. 95(1): p. 422-34.
7. Takagi, M., et al., Long-term outcomes in patients treated with proton therapy for localized prostate cancer. Cancer Med, 2017. 6(10): p. 2234-2243.
8. Colaco, R.J., et al., Rectal toxicity after proton therapy for prostate cancer: an analysis of outcomes of prospective studies conducted at the university of Florida Proton Therapy Institute. Int J Radiat Oncol Biol Phys, 2015. 91(1): p. 172-81.
9. Henderson, R.H., et al., Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials. Acta Oncol, 2013. 52(3): p. 463-9.
10. Valery, R., et al., Hip fractures and pain following proton therapy for management of prostate cancer. Acta Oncol, 2013. 52(3): p. 486-91.
11. Henderson, R.H., et al., Five-year outcomes from a prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer. Acta Oncol, 2017. 56(7): p. 963-970.
12. Vargas, C.E., et al., Image-guided hypofractionated proton beam therapy for low-risk prostate cancer: Analysis of quality of life and toxicity, PCG GU 002. Rep Pract Oncol Radiother, 2016. 21(3): p. 207-12.
13. Goenka, A., et al., Patient-reported Quality of Life After Proton Beam Therapy for Prostate Cancer: The Effect of Prostate Size. Clin Genitourin Cancer, 2017. 15(6): p. 704-710.
14. Widesott, L., et al., Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis. Int J Radiat Oncol Biol Phys, 2011. 80(5): p. 1589-600.
15. Chuong, M.D., et al., Minimal toxicity after proton beam therapy for prostate and pelvic nodal irradiation: results from the proton collaborative group REG001-09 trial. Acta Oncol, 2017: p. 1-7.
16. Holtzman, A.L., et al., Proton Therapy as Salvage Treatment for Local Relapse of Prostate Cancer Following Cryosurgery or High-Intensity Focused Ultrasound. Int J Radiat Oncol Biol Phys, 2016. 95(1): p. 465-71
For more information, please contact Cheryl Savage, Administrator, Department of Radiation Medicine
Email: [email protected]
MedStar Georgetown University Hospital Proton Therapy Center is pleased to offer the most cutting-edge proton therapy technology available, providing the next generation of radiation medicine close to home. Contact us today to schedule a consultation and take the first step toward your recovery.